ATE438642T1 - Chinazolinderivate als egf- und/oder erbb2- tyrosinkinaseinhibitoren - Google Patents

Chinazolinderivate als egf- und/oder erbb2- tyrosinkinaseinhibitoren

Info

Publication number
ATE438642T1
ATE438642T1 AT06726942T AT06726942T ATE438642T1 AT E438642 T1 ATE438642 T1 AT E438642T1 AT 06726942 T AT06726942 T AT 06726942T AT 06726942 T AT06726942 T AT 06726942T AT E438642 T1 ATE438642 T1 AT E438642T1
Authority
AT
Austria
Prior art keywords
erbb2
egf
quinazoline derivatives
tyrosinkinase
inhibitors
Prior art date
Application number
AT06726942T
Other languages
English (en)
Inventor
Robert Hugh Bradbury
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE438642T1 publication Critical patent/ATE438642T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06726942T 2005-04-29 2006-04-27 Chinazolinderivate als egf- und/oder erbb2- tyrosinkinaseinhibitoren ATE438642T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0508715.0A GB0508715D0 (en) 2005-04-29 2005-04-29 Chemical compounds
PCT/GB2006/001562 WO2006117523A1 (en) 2005-04-29 2006-04-27 Quinazoline derivatives as egf and/or erbb2 tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE438642T1 true ATE438642T1 (de) 2009-08-15

Family

ID=34674047

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06726942T ATE438642T1 (de) 2005-04-29 2006-04-27 Chinazolinderivate als egf- und/oder erbb2- tyrosinkinaseinhibitoren

Country Status (9)

Country Link
US (1) US20090221616A1 (de)
EP (1) EP1877398B1 (de)
JP (1) JP2008539217A (de)
CN (1) CN101208331A (de)
AT (1) ATE438642T1 (de)
DE (1) DE602006008292D1 (de)
ES (1) ES2329508T3 (de)
GB (1) GB0508715D0 (de)
WO (1) WO2006117523A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026150A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
ATE413389T1 (de) 2004-02-03 2008-11-15 Astrazeneca Ab Chinazolinderivate
ATE501148T1 (de) * 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
ES2738864T3 (es) 2013-03-12 2020-01-27 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combinaciones de inhibidores de MEK, EGFR y ERBB2 en el tratamiento del cáncer de pulmón causado por un mutante de KRAS
EP3670496A3 (de) * 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Acc2 hemmer
EP3516071B1 (de) 2016-09-22 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von lungenkrebs
US11723891B2 (en) 2018-04-12 2023-08-15 Umc Utrecht Holding B.V. Drug combinations for use in the treatment of RAS-mutant cancer
ES2961187T3 (es) * 2019-06-21 2024-03-08 Hoffmann La Roche Inhibidor de EGFR para el tratamiento del cáncer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
US4921863A (en) * 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ID18666A (id) * 1996-01-31 1998-04-30 Gist Brocades Bv Penggunaan komposisi komposisi yang terdiri dari senyawa senyawa stabil yang efektif secara biologi
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6391874B1 (en) * 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
TR200102505T2 (tr) * 1999-02-27 2003-01-21 Boehringer Ingelheim Pharma Kg 4-amino-kinazolin ve kinolin türevleri.
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
US20040176361A1 (en) * 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
RU2004116911A (ru) * 2001-11-03 2005-11-10 Астразенека Аб (Se) Производные хиназолина в качестве противоопухолевых средств
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
CA2533345A1 (en) * 2003-07-29 2005-02-10 Astrazeneca Ab Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
WO2005026150A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
BRPI0414488A (pt) * 2003-09-16 2006-11-14 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti - proliferativo em um animal de sangue quente, para prevenção ou tratamento de tumores em um aminal de sangue quente, para fornecer um efeito inibidor da tirosina quinase de egfr seletivo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e, processo para a preparação de um derivado de quinazolina
MXPA06002963A (es) * 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
DE602004004811T2 (de) * 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
MXPA06003341A (es) * 2003-09-25 2006-06-08 Astrazeneca Ab Derivados de quinazolina.
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
ATE413389T1 (de) * 2004-02-03 2008-11-15 Astrazeneca Ab Chinazolinderivate
CA2567832A1 (en) * 2004-06-04 2005-12-15 Astrazeneca Ab Quinazoline derivatives as erbb receptor tyrosine kinases

Also Published As

Publication number Publication date
ES2329508T3 (es) 2009-11-26
GB0508715D0 (en) 2005-06-08
EP1877398B1 (de) 2009-08-05
HK1114385A1 (en) 2008-10-31
JP2008539217A (ja) 2008-11-13
EP1877398A1 (de) 2008-01-16
CN101208331A (zh) 2008-06-25
WO2006117523A1 (en) 2006-11-09
US20090221616A1 (en) 2009-09-03
DE602006008292D1 (de) 2009-09-17

Similar Documents

Publication Publication Date Title
GB0309009D0 (en) Quinazoline derivatives
NO20061321L (no) Kinazolinderivater som tyrosin kinase inhibitorer
HN2008000317A (es) Benzimidazoles sustituidos como inhibidores de cinasa
ATE499097T1 (de) Monozyklische heterozyklen als kinase-hemmer
NI201000059A (es) Inhibidores de la cinasa c-fms.
MX384087B (es) Piperidinas como inhibidores de menina.
DK2020996T3 (da) Fremgangsmåder og sammensætninger til behandling af hæmatologiske sygdomme
NZ580671A (en) Pyrimidine derivatives
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
ATE438641T1 (de) Chinazolinderivate als inhibitoren von egf und/oder erbb2-rezeptortyrosinkinase
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MA33721B1 (fr) Derives sulfonamides heterocycliques utilises comme inhibiteurs de mek
NZ589191A (en) Quinazoline derivatives that inhibit the activity of egfr
ATE554066T1 (de) Entzündungshemmende substituierte cyclobutendionverbindungen
UY28610A1 (es) Derivados de quinazolina
UA107689C2 (xx) ПОХІДНІ 3,4,4A,10B-ТЕТРАГІДРО-1H-ТІОПІРАНО$4, 3-c]ІЗОХІНОЛІНУ
MX2011007165A (es) Derivados de piridazinona.
DE602006008292D1 (de) Chinazolinderivate als egf- und/oder erbb2-tyrosinkinaseinhibitoren
PH12021550374A1 (en) Small molecule menin inhibitors
DE602007005628D1 (de) Derivate von pyrimidinen als flammschutzmittel
DE602005026865D1 (de) Pyrazolopyrimidinverbindungen als antitumormittel
MX2012013527A (es) Quinazolinas policíclicas, preparación de las mismas, y uso de las mismas.
TW200745090A (en) Chemical compounds
ATE443053T1 (de) Als inhibitoren von erbb-tyrosinkinase verwendete chinazoleinderivate
DE602005005024D1 (de) Substituierte thieno- und thiazoloä2,3-düpyrimidine und ä2,3-cüpyridine als inhibitoren von tie2

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties